New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer

Michelle E. Melisko, Michael Glantz, Hope S. Rugo

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

The introduction of trastuzumab for the treatment of tumors that overexpress ErbB2 (also known as HER2) has contributed significantly to recent improvements in systemic therapy for advanced breast cancer. The advances in systemic therapy have highlighted an increasing prevalence of central nervous system involvement in patients with ErbB2-positive breast cancer and a consequent need for new treatment options for brain metastases. Just as ErbB2-targeted systemic therapy has given rise to this challenge, so too could targeted therapy represent an opportunity to meet it. This Review considers the potential for targeted therapy to facilitate effective management of brain metastases in patients with ErbB2-positive breast cancer, and discusses in particular the data currently available in this setting for lapatinib, an orally available small-molecule tyrosine kinase inhibitor of ErbB1 and ErbB2.

Original languageEnglish (US)
Pages (from-to)25-33
Number of pages9
JournalNature Clinical Practice Oncology
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Brain
Therapeutics
Protein-Tyrosine Kinases
Central Nervous System
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{4919e34031034371aab1d978bf5e4745,
title = "New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer",
abstract = "The introduction of trastuzumab for the treatment of tumors that overexpress ErbB2 (also known as HER2) has contributed significantly to recent improvements in systemic therapy for advanced breast cancer. The advances in systemic therapy have highlighted an increasing prevalence of central nervous system involvement in patients with ErbB2-positive breast cancer and a consequent need for new treatment options for brain metastases. Just as ErbB2-targeted systemic therapy has given rise to this challenge, so too could targeted therapy represent an opportunity to meet it. This Review considers the potential for targeted therapy to facilitate effective management of brain metastases in patients with ErbB2-positive breast cancer, and discusses in particular the data currently available in this setting for lapatinib, an orally available small-molecule tyrosine kinase inhibitor of ErbB1 and ErbB2.",
author = "Melisko, {Michelle E.} and Michael Glantz and Rugo, {Hope S.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1038/ncponc1243",
language = "English (US)",
volume = "6",
pages = "25--33",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "1",

}

New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. / Melisko, Michelle E.; Glantz, Michael; Rugo, Hope S.

In: Nature Clinical Practice Oncology, Vol. 6, No. 1, 01.01.2009, p. 25-33.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer

AU - Melisko, Michelle E.

AU - Glantz, Michael

AU - Rugo, Hope S.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The introduction of trastuzumab for the treatment of tumors that overexpress ErbB2 (also known as HER2) has contributed significantly to recent improvements in systemic therapy for advanced breast cancer. The advances in systemic therapy have highlighted an increasing prevalence of central nervous system involvement in patients with ErbB2-positive breast cancer and a consequent need for new treatment options for brain metastases. Just as ErbB2-targeted systemic therapy has given rise to this challenge, so too could targeted therapy represent an opportunity to meet it. This Review considers the potential for targeted therapy to facilitate effective management of brain metastases in patients with ErbB2-positive breast cancer, and discusses in particular the data currently available in this setting for lapatinib, an orally available small-molecule tyrosine kinase inhibitor of ErbB1 and ErbB2.

AB - The introduction of trastuzumab for the treatment of tumors that overexpress ErbB2 (also known as HER2) has contributed significantly to recent improvements in systemic therapy for advanced breast cancer. The advances in systemic therapy have highlighted an increasing prevalence of central nervous system involvement in patients with ErbB2-positive breast cancer and a consequent need for new treatment options for brain metastases. Just as ErbB2-targeted systemic therapy has given rise to this challenge, so too could targeted therapy represent an opportunity to meet it. This Review considers the potential for targeted therapy to facilitate effective management of brain metastases in patients with ErbB2-positive breast cancer, and discusses in particular the data currently available in this setting for lapatinib, an orally available small-molecule tyrosine kinase inhibitor of ErbB1 and ErbB2.

UR - http://www.scopus.com/inward/record.url?scp=73949093137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949093137&partnerID=8YFLogxK

U2 - 10.1038/ncponc1243

DO - 10.1038/ncponc1243

M3 - Review article

VL - 6

SP - 25

EP - 33

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 1

ER -